Free Design Audit Available - Click Here for Details

FDA authorizes Watmind USA’s OTC COVID and flu test

Watmind USA announced that the FDA granted it emergency use authorization (EUA) for its SpeedySwab COVID + flu A&B self test.

EUA covers over-the-counter (OTC) and point-of-care (POC) use. The Jackson, Mississippi-based company developed the test in partnership with the NIH’s Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP).

Watmind USA aims to revolutionize home diagnostics. The company says it designed SpeedySwab to help symptomatic individuals aged two and older quickly identify if their symptoms occur due to COVID-19, Influenza A or Influenza B. With a user-friendly, step-by-step process, the test utilizes lateral flow assay (LFA) technology.

Sign up for Blog Updates